Oric Pharmaceuticals (ORIC) News Today $7.97 +0.04 (+0.50%) Closing price 04:00 PM EasternExtended Trading$8.04 +0.07 (+0.85%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ORIC Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC38 minutes ago | globenewswire.comCompanies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In GrowthMay 17 at 11:41 PM | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICMay 14, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICMay 12, 2026 | globenewswire.comWall Street Zen Downgrades Oric Pharmaceuticals (NASDAQ:ORIC) to Strong SellMay 9, 2026 | marketbeat.comCitigroup Cuts Oric Pharmaceuticals (NASDAQ:ORIC) Price Target to $16.00May 8, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICMay 7, 2026 | prnewswire.comQ2 EPS Estimate for Oric Pharmaceuticals Lowered by AnalystMay 7, 2026 | marketbeat.comCitigroup Lowers Oric Pharmaceuticals (NASDAQ:ORIC) Price Target to $16.00May 5, 2026 | marketbeat.comOric Pharmaceuticals (NASDAQ:ORIC) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPSMay 4, 2026 | marketbeat.comORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational UpdatesMay 4, 2026 | globenewswire.comOric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 2, 2026 | marketbeat.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICApril 30, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICApril 28, 2026 | globenewswire.comOric Pharmaceuticals (ORIC) to Release Earnings on MondayApril 27, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORICApril 21, 2026 | globenewswire.comORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American ...April 17, 2026 | markets.businessinsider.comORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual MeetingApril 17, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICApril 16, 2026 | prnewswire.comORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law FirmApril 15, 2026 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICApril 14, 2026 | globenewswire.comOric Pharmaceuticals shows market leadership with jump to 87 RS ratingApril 10, 2026 | msn.comA Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer DataApril 6, 2026 | finance.yahoo.comORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesApril 6, 2026 | globenewswire.comGuggenheim Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)April 3, 2026 | theglobeandmail.comOric Pharmaceuticals (ORIC) Receives a Buy from Evercore ISIApril 3, 2026 | theglobeandmail.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 3, 2026 | globenewswire.comOric Pharmaceuticals stock falls on prostate cancer trial data, Sellside CommentsApril 2, 2026 | za.investing.comORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3April 2, 2026 | finance.yahoo.comOric to advance prostate cancer drug to Phase III trialsApril 1, 2026 | yahoo.comORIC Pharma drops after early-stage trial data for prostate cancer therapyApril 1, 2026 | seekingalpha.comOric Pharmaceuticals Shares Fall on Side Effect Data in Prostate Cancer Drug TrialApril 1, 2026 | marketwatch.comWhat's behind the drop in Oric Pharmaceuticals stock today?April 1, 2026 | msn.comORIC Pharmaceuticals: Updates Did Not Bode Well For This ValuationApril 1, 2026 | seekingalpha.comWhat's Behind The Drop In Oric Pharmaceuticals Stock Today?April 1, 2026 | benzinga.comORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastatic Prostate Cancer TranscriptApril 1, 2026 | seekingalpha.comORIC Pharmaceuticals stock tumbles 27% after trial updateApril 1, 2026 | za.investing.comORIC falls after hours on safety concerns around prostate cancer candidate at higher dosesApril 1, 2026 | msn.comORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its ...April 1, 2026 | markets.businessinsider.comORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease ProfileMarch 31, 2026 | globenewswire.comORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPCMarch 27, 2026 | globenewswire.comORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual MeetingMarch 17, 2026 | globenewswire.comWhy ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Ipsen Pulls Tazverik Over Safety ConcernsMarch 13, 2026 | uk.finance.yahoo.comA Look At ORIC Pharmaceuticals (ORIC) Valuation After Recent Share Price VolatilityMarch 13, 2026 | finance.yahoo.comGilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls ExplainedMarch 10, 2026 | 247wallst.comOric Pharmaceuticals stock tumbles on Tazverik withdrawalMarch 9, 2026 | in.investing.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)March 6, 2026 | globenewswire.comOric Pharmaceuticals (NASDAQ:ORIC) CFO Sells $702,520.00 in StockFebruary 27, 2026 | insidertrades.comOric Pharmaceuticals price target raised to $25 from $23 at H.C. WainwrightFebruary 25, 2026 | finance.yahoo.com Get Oric Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ORIC Media Mentions By Week ORIC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORIC News Sentiment▼0.240.39▲Average Medical News Sentiment ORIC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORIC Articles This Week▼34▲ORIC Articles Average Week Get the Latest News and Ratings for ORIC and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Oric Pharmaceuticals and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Viking Therapeutics News Today Telix Pharmaceuticals News Today Twist Bioscience News Today Organon & Co. News Today Beam Therapeutics News Today Tango Therapeutics News Today Oruka Therapeutics News Today Arcus Biosciences News Today Erasca News Today Denali Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORIC) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oric Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oric Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
